Are China Hospital Purchases Slowing? Ask Mindray
This article was originally published in The Gray Sheet
Executive Summary
China’s largest medical device maker surprised everyone by posting overall second-quarter net revenue growth of 9 percent, to $334.5 million, amid challenging market conditions. It expects a further recovery in the second half, but conditions at home remain difficult.
You may also be interested in...
Pipeline Watch: 11 Approvals And Eight Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Worsening UK Pharma Sector Close To ‘Tipping Point,’ Warns GSK Chief
Dame Emma Walmsley has delivered a broadside to the UK government, urging it to reverse a raised revenues ‘clawback’ for pharma companies and boost new medicines uptake in order to maintain the UK’s competitiveness in life sciences.
Sanofi Consumer Healthcare Reaches 'Next Level Of Autonomy'
The integration of core business functions at Sanofi Consumer Healthcare represents the “next level of autonomy” for the business, according to group CFO Jean-Baptiste Chasseloup de Chatillon. “As a result, you can expect a much enhanced CHC disclosure, allowing you easy peer comparisons and our team benchmark will be easier and more compelling.” The move came as Sanofi Consumer Healthcare reported a strong end to 2022, with Q4 sales up by 6.6% at constant exchange rates to €1.22bn.